High-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) to consolidate first CR is proposed for AML patients who have favorable-or intermediate-risk karyotype abnormalities. [1] [2] [3] It provides substantial anti-leukemic efficacy without the morbidity and mortality of GvHD associated with allogeneic transplantation. Although successful mobilization of PBSC is a prerequisite for ASCT, mobilization failure in AML patients has been poorly studied so far. 4 Moreover, alternative strategies for AML patients with mobilization failure are limited to harvesting stem cells from the bone marrow and there are inconveniences associated with this procedure. Also, very limited experience is available on the use of the CXCR4 antagonist plerixafor as a rescue strategy in AML patients. 5 We have reported the use of the cytotoxic compound vinorelbine together with G-CSF as a fully ambulatory mobilization procedure allowing highly predictable collection of PBSC at day 8 in myeloma and lymphoma patients. [6] [7] [8] [9] In this retrospective study, we explored the potential of vinorelbine together with G-CSF as a remobilization procedure in AML patients in first remission with primary mobilization failure after two cycles of intensive chemotherapy. Patients were treated according to the SAKK/HOVON-42, -92 or -102 protocols and underwent PBSC mobilization if the genomic-based risk assessment indicated good-risk, intermediate-risk (in the absence of an HLA-identical sibling donor), or bad-risk (in the absence of a sibling and an unrelated matched donor) AML. The study period included all eligible patients treated at the University Hospital of Bern, Switzerland between May 2005 and January 2015, and the clinical characteristics of the patients are summarized in Table 1 . Abbreviations: ANC = absolute neutrophil count; EM = early mobilization; ELN = European Leukemia Net classification; FLT3-ITD = internal tandem duplication of the FLT3 gene; FLT3wt = wild-type FLT3 gene; FAB = French-American-British classification; MDS = myelodysplastic syndrome; MF = primary mobilization failure; NOS = not otherwise specified; NPM1mut = mutation in the Nucleophosmin 1 gene; NS = not significant; WBC = white blood cells.
This study was approved by the local ethics committee of Bern, Switzerland (decision number #220/15). G-CSF (filgrastim) stimulation at 10 μg/kg body weight (bw) was initiated on the first day of induction cycle 2 when neutrophils increased above 0.5 g/L. Stem cell collection was performed when the number of peripheral circulating CD34 + cells exceeded 20 000/mL as previously described. [10] [11] Patients were considered to have primary mobilization failure when the number of peripheral CD34
+ cells failed to exceed 20 000/mL despite continued filgrastim stimulation. After hematologic recovery, patients in CR1 with primary mobilization failure received 35 mg/m 2 of vinorelbine as a 10 min infusion (day 1). Filgrastim stimulation at 10 μg/kg bw/day was initiated on day 4 and continued until the day of stem cell collection. Collection was performed on the day when CD34 + cells exceeded 20 000/mL in the peripheral blood for the first time. 2 × 10 6 CD34 + cells/kg bw was the minimum collection requirement, and we aimed to collect between 3 to 5 × 10 6 CD34 + cells/kg bw. For HDCT, patients received oral busulfan 4 mg/kg bw every 6 h on days − 6 until − 3, and intravenous cyclophosphamide 60 mg/kg/day on days − 2 and − 1. A minimum of 2 × 10 6 CD34 + cells/kg bw was transfused on day 0.
We studied 85 AML patients with morphologic CR achieved after the first cycle of induction treatment (early CR1). Sixty-nine of 85 patients (81%) achieved PBSC mobilization, allowing the collection of at least 2 × 10 6 CD34 + cells/kg (early mobilizer group (EM)). In 16 patients (19%), insufficient PBSC mobilization was observed (mobilization failure (MF) group). AML patients in the MF group had higher numbers of platelets at diagnosis (109 versus 63 g/L; P = 0.0074), and patients with mutated NPM1 and wild-type FLT3 (NPM1mut-FLT3wt) were more common in the MF group (37.5 versus 14.5%; P = 0.0148).
The 16 MF patients received remobilization chemotherapy with vinorelbine (35 mg/m 2 ) and filgrastim stimulation after hematologic and physical recovery (median 81 days after the start of the second induction cycle; range 38-204 days). Nine of the 16 MF patients achieved numbers of peripheral CD34 + cells exceeding 20 000/mL allowing successful PBSC collection (successful remobilization (SR) subgroup), whereas seven patients also failed vinorelbine remobilization (MF2 subgroup). The collection procedure in the nine SR patients could be accomplished on a single day in seven patients (78%; three patients on day 8 and four patients on day 9), while two patients needed two (days 8 and 9) collection days (22%). The median number of circulating peripheral CD34 + cells at the day of stem cell collection was 46,774 cells/mL, and the median harvest of CD34 + PBSC was 6.65 × 10 6 /kg bw (Supplementary Table 1 ). The seven patients with mobilization failure following vinorelbine/ filgrastim treatment (MF2) subsequently received chemotherapy consolidation with mitoxantrone and etoposide. Three of them (43%) relapsed, without undergoing subsequent allogeneic transplantation because of disease refractory to salvage treatment (two patients) and extensive fungal infection (one patient).
The clinical characteristics of the primary mobilization failure (MF) group comparing patients with successful remobilization (SR) with vinorelbine/filgrastim versus patients with remobilization failure after vinorelbine/filgrastim treatment (MF2) are listed in Supplementary Table 2 . SR patients received the vinorelbine treatment earlier after the second induction cycle (63 days versus 103 days). Finally, three of the six NPM1mut-FLT3wt patients with primary mobilization failure were successfully remobilized with vinorelbine/filgrastim.
All patients undergoing HDCT before ASCT received the complete dose of busulfan and cyclophosphamide, with a median transfusion of 3.3 × 10 6 /kg bw. CD34 + PBSC (range 2.0-5.4 × 10 6 /kg). Neutrophils recovered above 0.5 g/L after a median of 12 days in both EM patients and SR patients (P = NS; range 9-40 days; and 10-15 days, respectively), and the median time until platelets increased above 20 g/L was 16 days (range 9-76) for EM patients and 34 days (range 13-62) for SR patients (P = NS). All patients ultimately achieved a complete hematologic recovery, and the median hospitalization duration was 24 days (range 16-37 days), with no differences between EM and SR patients.
We compared the survival rates of patients with early mobilization (EM; n = 69) to the group of patients with successful vinorelbine remobilization (SR; n = 9). The survival curves are depicted in Figure 1 , with a median follow-up of 31 and 43.6 months, respectively. So far, 34 of 69 patients (49%) in the EM group relapsed compared to 6 of 9 patients (66%) in the SR group. The six relapses in the SR group occurred after a median of 13.3 months (range 4-26 months) after ASCT, and the median duration from ASCT to relapse was 9.2 months in the EM group (range 2.5-76.3 months).
Thirty-five patients have died so far, with 31 patients (45%) in the EM group and 4 patients (44%) in the SR group. Five of 69 (7.3%) patients in the EM group died within 100 days after ASCT due to treatment-related mortality in one patient (TRM 1.4%) and to early progression of AML in four patients. No patient in the SR group died within the first 100 days. Sixteen of the 42 relapsing patients in the entire cohort ultimately received allogeneic transplantation in second remission (3 of the 6 relapsing patients in the SR group, and 13 of the 36 patients in the EM group). Four of the 16 patients (25%) with allogeneic transplantation died because of treatment-related mortality, whereas all other deaths after allogeneic transplantation were due to AML progression. An obvious prerequisite for ASCT is a successful collection of a sufficient number of stem and progenitor cells providing safe engraftment after high-dose conditioning treatment, and peripheral blood is the predominant source of stem cells nowadays. [1] [2] [3] 12 Although available data provide a reasonable basis to suggest that ASCT can be recommended to defined subgroups of AML patients, [13] [14] [15] there is little information on mobilization failure rates and on rescue strategies for AML patients with mobilization failure. We report in this retrospective single-center study of uniformly treated consecutive AML patients in first remission a 19% rate of mobilization failure among those patients in whom filgrastim treatment was effectively initiated after two cycles of induction treatment for subsequent peripheral stem cell collection. We failed to find comparable data in the literature; thus, our mobilization failure rate may serve as a basis for future trials applying ASCT consolidation in patients with AML.
The standard approach for AML patients in CR1 with mobilization failure of PBSC involves bone marrow collection or switching to conventional chemotherapy consolidation. Alternative chemo-mobilization has not been reported so far in AML patients. In this report, we evaluated our strategy to apply a single dose of non-myelosuppressive chemotherapy with 35 mg/m 2 vinorelbine on day 1 together with filgrastim started on day 4 in AML patients in CR1 with primary mobilization failure. We observed that more than half of the patients with mobilization failure achieve sufficient PBSC collection allowing such patients to proceed to HDCT with ASCT. We observed no differences in hematologic recovery in patients with successful remobilization compared to patients with conventional collection after induction treatment. In addition, progression-free and overall survival did not differ, suggesting that such patients may equally benefit from ASCT consolidation. The obvious limitations of this study are the small sample size and its retrospective and single-center design. Nevertheless, this is the first study reporting on the use of a remobilization chemotherapy regimen in AML patients, with a promising success rate of 56%.
